http://www.omegadiagnostics.com/home

Today the company announced the completion of the aquisition of Genesis and CNS.Reports have been posted and show both companies to be profitable and growing.Around 4.5M shares in free float in the market.Directors have purchased in the placing and are tied in until 2008.

Grab yourself a bargain on Monday.

Introduction
Omega Diagnostics Group PLC was established in September 2006 when Omega Diagnostics Limited completed a reverse acquisition of an AIM Listed Cash Shell Company called Quintessentially English PLC.

Omega Diagnostics Limited (Omega) is an established business in the medical diagnostics market. Omega sells a wide range of products primarily in the immunoassay and infectious disease in-vitro diagnostics (IVD) market through a strong distribution network in over 100 countries. Omega has grown organically since incorporation and in the year ended 31 March 2006 sales were approximately 2.1 million. As at 31 March 2006, the Company employed 22 staff at its 10,330 square foot facility in Alva, Central Scotland.

Omega operates in a niche market, in supplying tests for specific infectious diseases and other clinical conditions. The tests are based on Agglutination, Enzymeimmunoassay (EIA), Fluorescence and Rapid Test technologies. The infectious diseases include Syphilis, TB, Dengue Fever and Malaria.

All products are designed for use in Clinical Laboratories and Rapid Tests are designed for use at the point of care.

Omega currently exports over 95 per cent. of its products. Omegas export success was officially recognised with the Queens Award for Export Achievement in 1993.

INFORMATION ON GENESIS-CNS

Genesis and CNS are established businesses in the medical diagnostics industry
which develop, produce and sell a range of IVD tests kits specialising in the
areas of autoimmune disease, infectious disease and food intolerance. The
acquisition of Genesis-CNS is in line with Omega's strategy of focusing on
selected acquisitions of niche players in the IVD market. Genesis-CNS has the
following characteristics which make it an attractive acquisition for the
Company:

- Growing, profitable, cash-generative

- Operating in growth markets

- Ability to increase the routes to market

- Complementary product ranges

- Well established high quality management team

this ones been on my watch list for a while
was put off intially as they were tipped by ic @ 19p !
now down to c.14p
anyone holding, or any views ???

Just bought in last couple of weeks looks an interesting little company with lots of upside imho/

Great set of Results.

Looking like a sure fire takeover target at these prices. One large company just paid 16x market price for a competor. Read results says about the valuation in them.

BUY

http://www.growthcompany.co.uk/recommendations/1635553/omega-diagnostics.thtml

Is nobody interested?

Watching closely leedslad!

http://www.edisoninvestmentresearch.co.uk/researchreports/omega080711outlook.pdf

price target 33p low 70p high

Looks like i am here on my own.

Too good to miss?

Good update today. Onwards and upwards imho

Seymour Pierce initiates buy on Omega Diagnostics, target price 26p.

Director Deals - Omega Diagnostics Group PLC (ODX)
BFN
Kieron Harbinson, Financial Director, bought 90,000 shares in the company on the 30th January 2012 at a price of 11.00p. The Director now holds 294,150 shares.

Story provided by StockMarketWire.com
Director deals data provided by www.directorsholdings.com


Nice director buy. Showing confidance ??

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")



FINAL RESULTS

FOR THE YEAR ENDED 31 MARCH 2012



Omega, the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces final results for the year ended 31 March 2012.



Omega is one of the UK's leading companies in the fast growing area of food intolerance and also operates in markets supplying tests for allergies and autoimmune diseases and specific infectious diseases through a strong distribution network in over 100 countries, a direct presence in Germany and India, and with a growing network of global partnerships.



Financial Highlights:
· Turnover up 41% to £11.1m (2011: £7.9m)

· Allergy and autoimmune revenue up 191% to £4.48m (2011: £1.54m)

· Food Intolerance revenue up 10% to £3.90m (2011: £3.56m)

· Infectious disease/other revenue down 2% to £2.75m (2011: £2.80m)

· Gross profit up 49% to £7.0m (2011: £4.7m)

· Adjusted profit before tax up 36% to £1.0m (2011: £0.74m)

· Adjusted EPS 1.2p (2011: 1.7p)

· Net cash generated from operations of £0.69m (2011: £0.35m)

· Cash at year end of £1.16m (2011: £2.05m) - reflecting iSYS development expenditure

· Net debt at the period end of £0.1m (2011: net cash of £0.45m)



Operational highlights:

· iSYS development programme; first batch of six allergens moving through optimisation with a further 18 allergens having commenced optimisation.

· Increase in average revenue per Genarrayt®system (excluding Spain) by 25% to £10,783.

· Strengthening of the Board with key appointment of Jag Grewal as Sales and Marketing Director.

· Direct access to Indian market achieved with incorporation of fully owned subsidiary Omega Dx (Asia) Pvt Ltd.

· Signing of license agreements with the Burnet Institute, Melbourne ("the Burnet") for worldwide rights to Point-of-Care ("POC") tests for CD4 and Syphilis with post year end production of first prototype CD4 test passing preliminary evaluation at the Burnet.



Regarding outlook, David Evans, Chairman, said:

"As the Group looks to build on its progress to date, it is clear that to achieve significant year-on-year growth we either need to increase the level of automation for customers or to provide POC tests to provide solutions for unmet needs in developing markets. From a market perspective, a focus on the growing BRIC countries is expected to yield above average results. In particular, I believe the opportunity with CD4, which will commercially launch in July, offers the Group an ability to create significant strategic value based on the responses we

This is gonna be multi bagger from here. imho

Am i the only one interested in these?
Fincap moved target price fron 21p to 25 on 21st june

Shame nobody here is wanting to make money getting lonely here lol